Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $959,200.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 220,000 shares of the company’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $4.36, for a total transaction of $959,200.00. Following the completion of the transaction, the director owned 6,649,863 shares in the company, valued at approximately $28,993,402.68. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, December 2nd, Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $4.37, for a total value of $961,400.00.

Recursion Pharmaceuticals Price Performance

RXRX stock traded down $0.16 during midday trading on Thursday, reaching $4.70. The company had a trading volume of 17,070,189 shares, compared to its average volume of 21,434,861. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.60 and a quick ratio of 4.60. The company has a market capitalization of $2.44 billion, a price-to-earnings ratio of -2.61 and a beta of 0.95. The stock has a 50 day moving average price of $4.50 and a 200-day moving average price of $5.07. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. The firm had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $19.36 million. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The business’s revenue for the quarter was down 80.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.34) earnings per share. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on RXRX. UBS Group set a $11.00 price objective on Recursion Pharmaceuticals in a report on Wednesday, December 17th. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $10.00 to $11.00 in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $9.40.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently made changes to their positions in RXRX. TD Waterhouse Canada Inc. increased its position in Recursion Pharmaceuticals by 64.1% during the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after acquiring an additional 2,200 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Recursion Pharmaceuticals by 97.2% during the second quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock valued at $46,000 after purchasing an additional 4,446 shares during the last quarter. Allworth Financial LP increased its position in Recursion Pharmaceuticals by 85.6% during the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after acquiring an additional 4,403 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $51,000. Finally, IFP Advisors Inc boosted its position in Recursion Pharmaceuticals by 81.5% in the 3rd quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock valued at $51,000 after buying an additional 4,650 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.